Results from late-breaking clinical trials sessions at ACCIS '99 and ACC '99. American College of Cardiology.
Morris
D C
DC
Emory Heart Center, Atlanta, Georgia 30322, USA.
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001550:Benzamidines / Q000627:therapeutic use; D017023:Coronary Angiography; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000188:drug therapy / Q000601:surgery / Q000628:therapy; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D009204:Myocardial Revascularization; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D019821:Simvastatin / Q000627:therapeutic use; D015607:Stents; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000924:Anticholesteremic Agents; D000925:Anticoagulants; D001550:Benzamidines; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; C081981:lanoteplase; D019821:Simvastatin; D010959:Tissue Plasminogen Activator; C091295:xemilofiban; D000077284:Abciximab